Novartis AG Profit Margin 2006-2020 | NVS

Current and historical gross margin, operating margin and net profit margin for Novartis AG (NVS) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Novartis AG net profit margin as of March 31, 2020 is 24.97%.
Novartis AG Annual Profit Margins
Novartis AG Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $200.372B $47.498B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $391.896B 16.75
Roche Holding AG (RHHBY) Switzerland $296.882B 0.00
Pfizer (PFE) United States $212.139B 13.17
Merck (MRK) United States $203.745B 14.76
Novo Nordisk (NVO) Denmark $155.276B 25.86
Eli Lilly (LLY) United States $146.289B 23.68
AstraZeneca (AZN) United Kingdom $143.291B 29.51
AbbVie (ABBV) United States $136.850B 10.05
Bristol-Myers Squibb (BMY) United States $135.128B 11.29
Sanofi (SNY) $122.978B 14.23
GlaxoSmithKline (GSK) United Kingdom $105.157B 12.55
Bayer (BAYRY) Germany $63.786B 9.10
H Lundbeck (HLUYY) Denmark $7.631B 13.26
Innoviva (INVA) United States $1.415B 8.17